Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Fischer Medical
Quarter-by-quarter operating performance
| Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 21 | 10 | 40 | 12 | 49 | 23 | 86 | 101 |
| Expenses + | 0 | 18 | 10 | 39 | 11 | 47 | 19 | 70 | 80 |
| Operating Profit | 0 | 3 | -0 | 0 | 0 | 2 | 4 | 16 | 22 |
| OPM % | 12% | -2% | 1% | 3% | 5% | 18% | 19% | 21% | |
| Other Income + | 0 | 0 | 1 | 0 | 0 | 0 | 7 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 3 | 0 | 0 | 0 | 2 | 10 | 17 | 21 |
| Tax % | 6% | 271% | -38% | 350% | 28% | 51% | 19% | 9% | |
| Net Profit + | 0 | 3 | -0 | 0 | -0 | 1 | 5 | 14 | 19 |
| EPS in Rs | 0.00 | 0.05 | -0.00 | 0.01 | -0.01 | 0.02 | 0.08 | 0.21 | 0.30 |
Financials of Fischer Medical
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|
| Sales + | 0 | 21 | 111 | 260 |
| Expenses + | 0 | 19 | 108 | 216 |
| Operating Profit | 0 | 2 | 3 | 44 |
| OPM % | 11% | 9% | 3% | 17% |
| Other Income + | 0 | 0 | 1 | 11 |
| Interest | 0 | 0 | 0 | 2 |
| Depreciation | 0 | 0 | 2 | 3 |
| Profit before tax | 0 | 2 | 2 | 50 |
| Tax % | 13% | 45% | ||
| Net Profit + | -0 | 2 | 1 | 39 |
| EPS in Rs | -0.24 | 0.03 | 0.02 | 0.61 |
| Dividend Payout % | 0% | 0% | 22% |
Financials of Fischer Medical
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|
| Equity Capital | 0.17 | 54 | 64 | 65 |
| Reserves | -0 | 28 | 274 | 295 |
| Borrowings + | 1 | 2 | 85 | 30 |
| Other Liabilities + | 0 | 4 | 34 | 77 |
| Total Liabilities | 0 | 86 | 457 | 468 |
| Fixed Assets + | 0 | 15 | 24 | 31 |
| CWIP | 0 | 0 | 1 | 2 |
| Investments | 0 | 1 | 11 | 121 |
| Other Assets + | 0 | 70 | 421 | 313 |
| Total Assets | 0 | 86 | 457 | 468 |
Financials of Fischer Medical
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Cash from Operating Activity + | -7 | -87 | |
| Cash from Investing Activity + | -29 | -125 | |
| Cash from Financing Activity + | 37 | 315 | |
| Net Cash Flow | 1 | 103 | |
| Free Cash Flow | -8 | -93 | |
| CFO/OP | -392% | -3,001% |
Financials of Fischer Medical
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 345 | 398 | 251 |
| Inventory Days | 99 | 36 | |
| Days Payable | 48 | 82 | |
| Cash Conversion Cycle | 345 | 449 | 205 |
| Working Capital Days | 324 | 498 | 40 |
| ROCE % | 5% | 1% |
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…
Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities. Key concall takeaways…
Ongoing construction and CAPEX of about INR 25-30 crores for capacity expansion at Khopoli and Nagpur hospitals. Key concall takeaways from Vaidya Sane's Q2…